Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ORAMED PHARMACEUTICALS INC.

ORMP · Nasdaq · CIK 0001176309 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

12 Form 4 transaction lines observed in the same window
4 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2023-04-04 · Mayer Arie · $8.4K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Hexter JoshuaCOO & CBO
▼○○▼
Gabay AvrahamChief Financial Officer
▼○▼
KIDRON NADAVPresident and CEO
○
Kidron MiriamChief Scientific Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-04-04 · Mayer Arie.

Recent Form 4 activity

0Purchases
4Sales
36Other Form 4 lines
28SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING4 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,433,436
Previous report
1,307,745
Avg daily volume
195,596
Days to cover
7.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-04-04Mayer AriePurchase (P)Common Stock3,800USD 2.21USD 8,398SEC filing ↗
2023-04-03Mayer AriePurchase (P)Common Stock5,009USD 2.22USD 11,120SEC filing ↗
2023-03-16KIDRON NADAVPurchase (P)Common Stock26,000USD 2.04USD 53,040SEC filing ↗
2023-03-14Rozov YadinPurchase (P)Common Stock50,000USD 2.05USD 102,500SEC filing ↗
2023-03-14KIDRON NADAVPurchase (P)Common Stock100,000USD 2.01USD 201,000SEC filing ↗
2023-03-13Rozov YadinPurchase (P)Common Stock20,000USD 1.96USD 39,200SEC filing ↗

Form 4 evidence

40 transaction lines in the latest 365-day window; 176 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Hexter JoshuaSale (S)Common Stock30,000USD 4.51USD 135,330SEC filing ↗
2026-10-01Gabay AvrahamSale (S)Common Stock20,000USD 4.51USD 90,200SEC filing ↗
2026-09-24Kidron MiriamAward / grant (A)Common Stock417,416USD —USD —SEC filing ↗
Show recent Form 4 evidence (29 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Hexter JoshuaSale (S)Common Stock30,000USD 4.51USD 135,330SEC filing ↗
2026-10-01Gabay AvrahamSale (S)Common Stock20,000USD 4.51USD 90,200SEC filing ↗
2026-09-24Kidron MiriamAward / grant (A)Common Stock417,416USD —USD —SEC filing ↗
2026-09-24KIDRON NADAVAward / grant (A)Common Stock718,262USD —USD —SEC filing ↗
2026-09-24Hexter JoshuaAward / grant (A)Common Stock284,746USD —USD —SEC filing ↗
2026-09-24Gabay AvrahamAward / grant (A)Common Stock209,291USD —USD —SEC filing ↗
2026-07-02Hexter JoshuaOption exercise / conversion (M)Common Stock50,000USD 3.69USD 184,500SEC filing ↗
2026-07-01Hexter JoshuaSale (S)Common Stock137,000USD 4.46USD 611,020SEC filing ↗
2026-07-01Gabay AvrahamSale (S)Common Stock73,360USD 4.51USD 330,854SEC filing ↗
2026-03-30Kidron MiriamTax withholding (F)Common Stock435,084USD 3.31USD 1,440,128SEC filing ↗
2026-03-30KIDRON NADAVTax withholding (F)Common Stock44,818USD 3.31USD 148,348SEC filing ↗
2026-03-17Kidron MiriamAward / grant (A)Common Stock119,558USD 0.00USD 0SEC filing ↗
2026-03-17KIDRON NADAVAward / grant (A)Common Stock167,005USD 0.00USD 0SEC filing ↗
2026-03-17Hexter JoshuaAward / grant (A)Common Stock95,889USD 0.00USD 0SEC filing ↗
2026-03-17Gabay AvrahamAward / grant (A)Common Stock95,889USD 0.00USD 0SEC filing ↗
2026-03-12KIDRON NADAVGift (G)Common Stock100,000USD 0.00USD 0SEC filing ↗
2026-01-22Kidron MiriamOption exercise / conversion (M)Common Stock19,000USD 0.00USD 0SEC filing ↗
2026-01-22KIDRON NADAVOption exercise / conversion (M)Common Stock109,000USD 0.00USD 0SEC filing ↗
2026-01-22Hexter JoshuaOption exercise / conversion (M)Common Stock19,000USD 0.00USD 0SEC filing ↗
2026-01-22Gabay AvrahamOption exercise / conversion (M)Common Stock19,000USD 0.00USD 0SEC filing ↗
2026-01-14Kidron MiriamGift (G)Common Stock86,166USD 0.00USD 0SEC filing ↗
2025-12-31Shapiro BenjaminAward / grant (A)Common Stock33,500USD —USD —SEC filing ↗
2025-12-31Reznick YehudaAward / grant (A)Common Stock36,250USD —USD —SEC filing ↗
2025-12-31Mayer ArieAward / grant (A)Common Stock34,900USD —USD —SEC filing ↗
2025-12-31Kidron MiriamAward / grant (A)Common Stock236,331USD 0.00USD 0SEC filing ↗
2025-12-31KIDRON NADAVAward / grant (A)Common Stock559,640USD 0.00USD 0SEC filing ↗
2025-12-31Hexter JoshuaAward / grant (A)Common Stock212,328USD 0.00USD 0SEC filing ↗
2025-12-31Gabay AvrahamAward / grant (A)Common Stock196,216USD 0.00USD 0SEC filing ↗
2025-12-31Aghion DanielAward / grant (A)Common Stock36,250USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerORMP
CIK0001176309
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history176 transaction lines from 2021-02-26 to 2026-10-01
6 P purchase lines · 12 S sale lines · 158 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.